Also known as: BriaPro Therapeutics
BriaPro Therapeutics is a private pre-clinical immunotherapy company and subsidiary of BriaCell, focused on oncology assets including Bria-TILsRx, PKCδ inhibitors, and anti-B7-H3 antibodies. It was incorporated in 2023 and operates from West Vancouver, British Columbia.
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.
BriaCell Therapeutics transfers exclusive license for Soluble CD80 cancer therapy to subsidiary BriaPro in deal valued at C$1.18 million, with BriaCell retaining 78% stake and providing $3 million credit facility.
